Staphylococcus Aureus Bacteremia (SAB) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Staphylococcus aureus bacteremia (SAB) is a severe bloodstream infection linked to significant illness and death. It leads to various complications, such as infective endocarditis, device-related infections, osteoarticular metastases, pleuropulmonary issues, and recurrent infections. Initially, SAB was categorized into healthcare-associated and community-acquired types. However, with advancements in molecular differentiation and understanding, a new classification emerged: healthcare-associated community-onset. Presently, SAB is categorized into three groups: community-acquired, healthcare-associated community-onset, and healthcare-associated hospital-onset. Community-acquired SAB pertains to individuals without prior healthcare contact, including injection drug users and those with spontaneous osteoarticular infections. These cases often present with multiple complications like endocarditis, renal failure, shock, respiratory distress, or disseminated intravascular coagulation. Healthcare-associated community-onset SAB encompasses patients with recent healthcare exposure, such as hospitalization within the past 90 days, receiving intravenous therapy, wound care, skilled nursing, or residing in healthcare facilities. Healthcare-associated hospital-onset SAB refers to infections contracted within healthcare settings. It is commonly associated with central-line infections, ventilator-associated pneumonia, or surgical site infections. Methicillin-resistant strains often cause these cases and are a leading cause of nosocomial infections. Risk factors for SAB include age, underlying medical conditions, injection drug use, and the presence of intravascular catheters or prosthetic devices. Early recognition of these factors is crucial during patient assessment. SAB can be classified as complicated or uncomplicated. Uncomplicated cases are defined by exclusion of endocarditis, absence of implanted prostheses, negative follow-up blood cultures, defervescence within 72 hours of antibiotic therapy, and no evidence of metastatic infection. Complications of SAB may involve the central nervous system, embolic phenomena, metastatic infections, or recurrent infections within 12 weeks. Predictors of complicated SAB include community acquisition, persistently positive blood cultures, persistent fever, and systemic skin findings. Uncomplicated SAB typically requires at least two weeks of intravenous antibiotic therapy, while complicated cases necessitate four to six weeks. Treatment selection depends on methicillin susceptibility, with preferred agents including penicillinase-resistant penicillins, first-generation cephalosporins, vancomycin, and daptomycin. Beta-lactams, particularly anti-staphylococcal penicillins like nafcillin, are commonly used as first-line agents for MSSA bacteremia.

Thelansis’s “Staphylococcus Aureus Bacteremia (SAB) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Staphylococcus Aureus Bacteremia (SAB) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Staphylococcus Aureus Bacteremia (SAB) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Staphylococcus Aureus Bacteremia (SAB) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Staphylococcus Aureus Bacteremia (SAB) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033